May 8th 2024
During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
As CLL Approaches Expand, Sequencing Questions Arise
September 22nd 2022Doctors and patients who can stick with a regimen despite relatively minor adverse event will ultimately have more options later in the treatment journey, which could then lead to better long-term outcomes in chronic lymphocytic leukemia.
Read More
Ibrutinib/Venetoclax Combination Improves MRD Negativity in Blood, Marrow in CLL
August 25th 2022Data from the planned interim analysis of the FLAIR trial show that venetoclax plus ibrutinib can achieved minimal residual disease negativity in patient with treatment-naïve chronic lymphocytic leukemia.
Read More
FDA Approves New Tablet Form for Acalabrutinib
August 5th 2022Acalabrutinib’s new tablet formulation has been granted FDA approval for all current indications, including adult patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and relapsed or refractory mantle cell lymphoma.
Read More
Zanubrutinib Displays PFS Benefit Over Bendamustine/Rituximab in CLL and SLL
August 1st 2022In the first comparison of zanubrutinib vs chemoimmunotherapy, zanbrutinib was shown to improve progression-free survival in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, and may be less toxic.
Read More
Burger Details the Data to Help Choose Treatment in Chronic Lymphocytic Leukemia
July 3rd 2022During a Targeted Oncology case-based roundtable event, Jan A. Burger, MD, PhD, discussed data supporting the use of ibrutinib, acalabrutinib, and zanubrutinib for first-line treatment of chronic lymphocytic leukemia.
Read More
Ibrutinib/Venetoclax May Decrease Development of Resistance Mutations in Patients With CLL
June 29th 2022Findings from an analysis of the CAPTIVATE study imply that ibrutinib plus venetoclax may allow for effective subsequent retreatment with ibrutinib and/or venetoclax and enhance clinical benefit.
Read More
Acalabrutinib-Based Regimens Continue to Top Obinutuzumab Plus Chemotherapy in Treatment-Naïve CLL
June 4th 2022With roughly 5 years of follow-up, outcomes were more favorable with acalabrutinib with or without obinutuzumab vs obinutuzumab and chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia.
Read More
Acalabrutinib Shows Better Exposure-Adjusted Tolerability in R/R CLL
June 2nd 2022John F. Seymour, MBBS, PhD, discusses the results of a post-hoc analysis of adverse events in the phase 3 ELEVATE-RR trial comparing acalabrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Watch
Roundtable Discussion: Saba Reviews Testing, Therapies, and Toxicity With Participants
May 29th 2022Nakhle Saba, MD, reviewed testing, treatment, and treatment toxicity in a 71-year-old woman with chronic lymphocytic leukemia with a group of peers during a Targeted Oncology case-based roundtable event.
Read More
Complex R/R CLL Treatment Landscape Braces as Noncovalent Inhibitors Emerge
May 16th 2022Targeted agents, such as Bruton tyrosine kinase inhibitors, PI3K inhibitors, B-cell lymphoma 2 inhibitors, and venetoclax, have delivered improvements in quality of life, progression-free survival, and overall survival for relapsed/refractory chronic lymphocytic leukemia.
Read More